Interim results of a multicenter phase II trial of nab -paclitaxel ( nab -P) plus gemcitabine (G) for patients (Pts) with locally advanced pancreatic cancer (LAPC).
Lacy J, Portales F, Hammel P, Pazo Cid R, Manzano Mozo J, Kim E, Dowden S, Borg C, Sastre J, Bathini V, Terrebonne E, Lopez-Trabada D, Rivera F, Asselah J, Damiani A, Hwang J, Ong T, Nydam T, Shiansong Li J, Philip P. Interim results of a multicenter phase II trial of nab -paclitaxel ( nab -P) plus gemcitabine (G) for patients (Pts) with locally advanced pancreatic cancer (LAPC). Journal Of Clinical Oncology 2017, 35: 358-358. DOI: 10.1200/jco.2017.35.4_suppl.358.Peer-Reviewed Original ResearchDisease control rateAdverse eventsMetastatic PCQOL scoresTreatment phaseDay 1Investigator's choiceMulticenter phase II trialInterim resultsCycles of nabECOG performance statusImproved symptom scoresQLQ-PAN26 questionnairesAdvanced pancreatic cancerG treatmentPhase II trialUnacceptable adverse eventsEORTC QLQ-C30Quality of lifeMPACT trialUnresectable LAPCII trialMost patientsNab-paclitaxelPerformance status